ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2027

Efficacy and Safety of Tildrakizumab, a High-Affinity Anti–Interleukin-23p19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis in a Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study

Philip Mease1, Saima Chohan2, Ferran J. García Fructuoso3, Alice Gottlieb4, Michael Luggen5, Proton Rahman6, Siba Raychaudhuri7, Richard Chou8, Alan Mendelsohn9, Stephen Rozzo9 and Ana-Maria Orbai10, 1Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, 2Arizona Arthritis and Rheumatology Research, PLLC, Pheonix, AZ, 3Hospital CIMA Sanitas, Barcelona, Spain, 4Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, 5Cincinnati Rheumatic Disease Study Group, Inc, and Univ of Cincinnati College of Medicine, Cincinnati, OH, 6Memorial University of Newfoundland, Department of Medicine, St John's, Canada, 7Division of Rheumatology, Allergy & Clinical Immunology, University of California School of Medicine, Davis, and VA Medical Center Sacramento, Sacramento, CA, 8Division of Allergy, Immunology and Rheumatology, University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, 9Sun Pharmaceutical Industries, Inc., Princeton, NJ, 10Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD

Meeting: ACR Convergence 2020

Keywords: clinical trial, Interleukins, Psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2020

Title: Spondyloarthritis Including Psoriatic Arthritis – Treatment II: Emerging Therapies (2023–2027)

Session Type: Abstract Session

Session Time: 11:00AM-11:50AM

Background/Purpose: Tildrakizumab (TIL), a high-affinity anti–interleukin-23p19 monoclonal antibody, is approved to treat moderate to severe plaque psoriasis.1 The efficacy and safety of TIL up to week (W)52 in patients with psoriatic arthritis (PsA) was evaluated in a randomized, double-blind, placebo-controlled, multiple-dose, phase 2b study (NCT02980692).

Methods: Patients (pts) ≥18 years with active PsA2 were randomized 1:1:1:1:1 to TIL 200 mg every 4 weeks (Q4W) to W52, TIL 200 mg Q12W to W52, TIL 100 mg Q12W to W52, TIL 20 mg Q12W until W24 then TIL 200 mg Q12W to W52, or placebo Q4W until W24 then TIL 200 mg Q12W to W52. Efficacy assessments included ACR20/50/70, 75%/90%/100% improvement in Psoriasis Area and Severity Index, proportion of pts with residual minimal disease activity response; and mean change from baseline (BL) in HAQ-Disability Index, Leeds Dactylitis Index (LDI, pts with BL LDI ≥1), and Leeds Enthesitis Index (LEI, pts with BL LEI ≥1) to W52. Treatment-emergent adverse events (TEAEs) were recorded.

Results: Of 500 pts screened, 391 were randomized and received ≥1 dose of drug. Demographics and baseline disease characteristics were generally consistent across treatment arms (Table 1). Proportions of ACR20/50/70 responders were superior with TIL vs PBO through W24; after W24 rates of responses further increased for TIL 20→200 mg Q12W and PBO→200 mg Q12W through W52 (Figure). Other efficacy results are shown in Table 2. Overall, 252 (64.5%) patients had a TEAE, the most common being nasopharyngitis (8.4%) and upper respiratory tract infection (6.4%). Most TEAEs, including infections, were mild. One (0.3%) malignancy (intraductal proliferative breast lesion) occurred in the TIL 20→200 mg Q12W arm. Serious TEAEs were observed in 13 (3.3%) patients. One serious infection (chronic tonsillitis) was reported in the TIL 20 mg Q12W arm during the first 24 weeks. One case each of pyelonephritis and urinary tract infection were reported as TEAEs of special interest (both in the same patient in the TIL 100 mg Q12W arm).  No deaths or major adverse cardiac events occurred.

Conclusion: TIL was well tolerated and improved musculoskeletal and skin manifestations of PsA through W52.

References

  1. Reich, et al. Lancet 2017;390:276−88.
  2. Taylor, et al. Arthritis Rheum 2006;54:2665–73.


Disclosure: P. Mease, Amgen, 2, 5, 8, Bristol-Myers Squibb, 2, 5, Novartis, 2, 5, 8, Pfizer Inc, 2, 5, 8, Sun, 2, 5, UCB, 2, 5, 8, AbbVie, 2, 5, 8, Gilead, 2, 5, Janssen, 2, 5, 8, Eli Lilly, 2, 5, 8, Galapagos, 5, GlaxoSmithKline, 5; S. Chohan, Arizona Arthritis and Rheumatology Associates, 9; F. García Fructuoso, AbbVie, 2, 5, 8, Eli Lilly, 2, 5, 8, Gedeon Richter, 2, 5, 8, MedImmune, 2, 5, 8, Nichi-Iko, 2, 5, 8, Pfizer, 2, 5, 8, Sanofi-Aventis, 2, 5, 8, Takeda, 2, 5, 8, UCB, 2, 5, 8; A. Gottlieb, Janssen, 2, 5, Incyte, 2, 5, Novartis, 2, 5, 8, Xbiotech, 2, 9, Boehringer Ingelheim, 2, 5, UCB Pharma, 2, 5, 8, Beiersdorf, 5, Bristol-Myers Squibb, 2, 5, 8, Eli Lilly, 2, 5, 8, Sun Pharma, 2, 5, Leo Pharma, 5, Avotres Therapeutics, 5; M. Luggen, AbbVie, 2, 5, 8, Amgen, 2, 5, 8, Genentech, 2, 5, 8, Eli Lilly, 2, 5, 8, Nichi-Iko, 2, 5, 8, Novartis, 2, 5, 8, Pfizer, 2, 5, 8, R-Pharm, 2, 5, 8, Sun Pharmaceutical Industries, Inc, 2, 5, 8; P. Rahman, AbbVie, 5, 8, Amgen, 5, 8, Celgene, 5, 8, Eli Lilly, 5, 8, Janssen, 2, 5, 8, Novartis, 2, 5, 8, Pfizer, 5, 8, UCB, 5, 8, Abbott, 8, Centacor, 8, Merck, 8, Bristol Myers Squibb, 5, 8, Roche, 5; S. Raychaudhuri, AbbVie, 2, Janssen, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, Sun Pharmaceutical Industries, Inc., 2, Amgen, 5, Eli Lilly, 5; R. Chou, Sun Pharmaceutical Industries, Inc, 5; A. Mendelsohn, Sun Pharmaceutical Industries, Inc., 3, Johnson and Johnson, 1, 9; S. Rozzo, Sun Pharmaceutical Industries, Inc., 3; A. Orbai, Eli Lilly, 2, 5, Janssen, 2, 5, Novartis, 2, 5, Pfizer Inc, 5, UCB, 5, AbbVie, 2, Celgene, 2, Horizon, 2.

To cite this abstract in AMA style:

Mease P, Chohan S, García Fructuoso F, Gottlieb A, Luggen M, Rahman P, Raychaudhuri S, Chou R, Mendelsohn A, Rozzo S, Orbai A. Efficacy and Safety of Tildrakizumab, a High-Affinity Anti–Interleukin-23p19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis in a Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/efficacy-and-safety-of-tildrakizumab-a-high-affinity-anti-interleukin-23p19-monoclonal-antibody-in-patients-with-active-psoriatic-arthritis-in-a-randomized-double-blind-placebo-controlled/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-and-safety-of-tildrakizumab-a-high-affinity-anti-interleukin-23p19-monoclonal-antibody-in-patients-with-active-psoriatic-arthritis-in-a-randomized-double-blind-placebo-controlled/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology